Theravance Biopharma (NASDAQ:TBPH) Issues Quarterly Earnings Results, Misses Expectations By $0.16 EPS

Theravance Biopharma (NASDAQ:TBPH) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.16), Zacks reports. The business had revenue of $16.87 million during the quarter, compared to analysts’ expectations of $16.11 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.23%. During the same period in the previous year, the business posted ($0.17) EPS.

Theravance Biopharma Price Performance

Shares of NASDAQ TBPH traded up $0.93 during trading hours on Wednesday, reaching $9.84. The stock had a trading volume of 171,117 shares, compared to its average volume of 345,828. Theravance Biopharma has a twelve month low of $7.44 and a twelve month high of $11.71. The company has a market cap of $481.39 million, a price-to-earnings ratio of -9.92 and a beta of 0.25. The business’s fifty day moving average is $8.32 and its two-hundred day moving average is $8.68.

Analysts Set New Price Targets

TBPH has been the subject of several recent analyst reports. Leerink Partnrs cut shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 6th. StockNews.com cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th. Leerink Partners downgraded shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $15.00 to $10.00 in a research report on Tuesday, August 6th. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Theravance Biopharma in a research report on Monday, September 16th. Finally, TD Cowen dropped their target price on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating for the company in a research report on Tuesday, August 6th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $13.75.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.